← All trials
NCT04661280
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2021
- Primary completion
- Feb 28, 2023
- Completion date
- Aug 31, 2023
- First posted
- Dec 10, 2020
- Last posted
- Dec 10, 2020
- Enrollment
- 240
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Assistance Publique - Hôpitaux de ParisLead sponsor
- Association France Alzheimer Et Maladies ApparentéesCollaborator
- France AlzheimerCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.